As CagriSema Falls Short Again, M&A Could Be Novo’s Surest Shot In The Arm
Analysts think Novo could deploy as much as $35bn in M&A firepower to help turnaround its fortunes this year.
Scrip - February 23, 2026

Neuroscience’s Reimbursement Problem
Device-based neurotherapeutics face a coverage gap that drug developers do not, and as the field moves toward combination approaches, that asymmetry could undermine important innovation.
In Vivo - February 23, 2026

Moberg Entering ‘New Phase’ Of European Expansion
Moberg's success in Scandinavia gives the company the confidence that its upcoming expansion across Europe will be a success.
HBW Insight - February 23, 2026

Lupin Confident In Soon-To-Be-Launched Pegfilgrastim Biosimilar Despite Crowded Market
Lupin is riding a wave of growth across most of its global markets, with biosimilars and other complex products filling its portfolio.
Generics Bulletin - February 23, 2026

Are Europe’s Self-Care Markets Stagnating?
Despite 2025 volume stagnation in France and Italy, structural opportunities in category penetration, wellness premiumization, pharmacy expansion, and Rx-to-OTC switch suggest the self-care market still has clear levers for growth.
HBW Insight - February 23, 2026

Pressure, Pivot And The Promise Of AI: BCG Maps Biopharma’s Defining Challenges For 2026
Recent BCG reports and interviews reveal an industry under pressure and racing to adapt through AI, new deal structures and direct-to-patient models.
In Vivo - February 23, 2026

FDA Says Yes To Dr Reddy’s Orencia Biosimilar Review
Dr Reddy’s remains on track for a potential late 2026 US approval for its proposed biosimilar to Orencia (abatacept), after the company’s BLA filing was accepted for review.
Generics Bulletin - February 23, 2026

Abivax Strengthens Case For Obefazimod With ECCO Data Drop
The spotlight remains firmly on the French biotech’s prized inflammatory bowel disease asset.
Scrip - February 23, 2026

Pipeline Watch: Four Approvals And Four Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - February 23, 2026

Google DeepMind’s Kohli On The New Era Of Digital Biology, AI Co-scientist
Google DeepMind’s vice president, science and strategic initiatives, talks about the potential of the group’s new generation of AI models designed to address problems across biology, heralding a new era of science and medical advances.
Scrip - February 23, 2026

Sawai Prepares For April 2026 Overhaul Of Japan’s Drug Pricing System
Sawai is anticipating that sweeping regulatory reforms due in April 2026 will reshape Japan’s generic drug market, altering pricing mechanics, margin structures and competitive dynamics.
Generics Bulletin - February 23, 2026

Gilead Acquires Anito-Cel Partner Arcellx Ahead Of US FDA Decision
Gilead’s takeover of Arcellx tightens its grip on anito-cel as it readies for a US FDA ruling and a high stakes entry into the crowded myeloma market.
Scrip - February 23, 2026

20 Voices: What Does 2026 Hold For Biopharma?
Twenty biopharma leaders share predictions for 2026 – from shifting dealmaking dynamics and Asia's rise as an innovation epicenter to new frontiers in oncology, obesity and cell therapy, and AI's operational reckoning.
In Vivo - February 23, 2026

Vanda Gains Branded Successor To Fanapt As US FDA Approves Another Antipsychotic
As Vanda prepares to shift promotional focus from Fanapt ahead of generic competition, Bysanti’s approval and pending MDD readout are expected to play a key role in sustaining momentum within the company’s psychiatry portfolio.
Scrip - February 23, 2026

Another Blow For Novo As CagriSema Can’t Match Zepbound Head-To-Head
Novo’s combination drug achieved 20.2% weight loss compared with Zepbound’s 23.6% in REDEFINE 4, dealing another blow to its hopes of regaining lost ground.
Scrip - February 23, 2026

Big Promises, Long Timelines – Trump’s US Pharma Investment Push
While investment promises appear to be in billions of dollars, industry experts remain skeptical.
In Vivo - February 23, 2026

US Supreme Court’s Tariff Authority Ruling Leaves Clouds Hanging Over Refunds, ‘Other Levers’
“The president is certainly hamstrung in many ways by this ruling. For businesses, there's still just sort of a lot of general uncertainty in regard to what else is the president going to try to do, what other authorities might he try to pull,” says Tax Foundation analyst Alex Durante.
HBW Insight - February 23, 2026